WITHDRAWN: 2-Arylquinazolin-4(3H)-ones: A new class of α-glucosidase inhibitors

[1]  M. Choudhary,et al.  Synthesis and β-glucuronidase inhibitory activity of 2-arylquinazolin-4(3H)-ones. , 2014, Bioorganic & medicinal chemistry.

[2]  Ghada S. Hassan,et al.  Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones. , 2013, European journal of medicinal chemistry.

[3]  Tuan-Anh N. Pham,et al.  Synthesis and biological evaluation of novel 2,4-disubstituted quinazoline analogues as GPR119 agonists. , 2013, Bioorganic & medicinal chemistry.

[4]  Shin-Duk Kim.  α-Glucosidase inhibitor from Buthus martensi Karsch. , 2013, Food chemistry.

[5]  Can Zhang,et al.  Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases. , 2012, European journal of medicinal chemistry.

[6]  P. Crooks,et al.  3-[Benzimidazo- and 3-[benzothiadiazoleimidazo-(1,2-c)quinazolin-5-yl]-2H-chromene-2-ones as potent antimicrobial agents. , 2011, Bioorganic & medicinal chemistry letters.

[7]  Mahmud Tareq Hassan Khan,et al.  Alpha-glucosidase and tyrosinase inhibitors from fungal hydroxylation of tibolone and hydroxytibolones , 2010, Steroids.

[8]  Mahmud Tareq Hassan Khan,et al.  Identification of novel quinazolin-4(3H)-ones as inhibitors of thermolysin, the prototype of the M4 family of proteinases. , 2010, Bioorganic & medicinal chemistry.

[9]  R. Tundis,et al.  Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update , 2010 .

[10]  K. Kavitha,et al.  Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H(1)-antihistaminic agents. , 2008, European journal of medicinal chemistry.

[11]  S. Murugesan,et al.  Synthesis of 4-butyl-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H(1)-antihistaminic agents. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  B. Zinman,et al.  Impaired Fasting Glucose and Impaired Glucose Tolerance , 2007, Diabetes Care.

[13]  Ivone Carvalho,et al.  α- and β-Glucosidase inhibitors: chemical structure and biological activity , 2006 .

[14]  Petro Petrides1.  Anagrelide: What Was New in 2004 and 2005? , 2006, Seminars in thrombosis and hemostasis.

[15]  T. Gefflaut,et al.  Synthesis of new nitrogen analogues of salacinol and deoxynojirimycin and their evaluation as glycosidase inhibitors. , 2006, The Journal of organic chemistry.

[16]  F. Birke,et al.  Pyrrolidinohydroquinazolines--a novel class of CCR3 modulators. , 2005, Bioorganic & medicinal chemistry letters.

[17]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Venkateswarlu,et al.  Synthesis and biological evaluation of [4-(2-phenylethenesulfonylmethyl)phenyl]-quinazolin-4-yl-amines as orally active anti-cancer agents. , 2004, Bioorganic & medicinal chemistry letters.

[19]  M. Kizaki,et al.  Capsaicin-Like Anti-Obese Activities of Evodiamine from Fruits of Evodia rutaecarpa, a Vanilloid Receptor Agonist , 2001, Planta medica.

[20]  K. Schrör,et al.  Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis. , 2000, Biochemical pharmacology.

[21]  N Zitzmann,et al.  Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Riendeau,et al.  Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes. , 1999, European journal of pharmacology.

[23]  Y. Kurogi,et al.  Synthesis and hypolipidemic activities of novel 2-[4-[diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3H)-quinazolinones. , 1996, Journal of medicinal chemistry.

[24]  M. Davies,et al.  Impaired glucose tolerance , 1996, BMJ.

[25]  M. Poli,et al.  Prophylaxis and treatment with a monoclonal antibody of tetrodotoxin poisoning in mice. , 1995, Toxicon : official journal of the International Society on Toxinology.

[26]  M. Niimura,et al.  Photoleukomelanodermatitis (Kobori) Induced by Afloqualone , 1994, The Journal of dermatology.

[27]  H. Holmsen.  Significance of testing platelet functions in vitro , 1994, European journal of clinical investigation.

[28]  F. Rousseau.  The fragile X syndrome: implications of molecular genetics for the clinical syndrome , 1994, European journal of clinical investigation.

[29]  J. Groopman.  Current advances in the diagnosis and treatment of AIDS: an introduction. , 1990, Reviews of infectious diseases.

[30]  V. Ram,et al.  Chemotherapeutic agents XI: synthesis of pyrimidines and azolopyrimidines as leishmanicides☆ , 1990 .

[31]  M. Scheinbaum,et al.  R013-6438, a new inotrope-vasodilator: Systemic and coronary hemodynamic effects in congestive heart failure , 1985 .

[32]  G. Belz,et al.  Dose‐Response Following Single Administrations of a New Cardiac Performance Enhancer RO 13–6438 in Normal Volunteers , 1985, Journal of cardiovascular pharmacology.

[33]  M. Gerold,et al.  Cardiovascular Profile of Ro 13–6438, a Novel Positive Inotropic Agent with Vasodilating Properties , 1984, Journal of cardiovascular pharmacology.

[34]  Amer Ms,et al.  Effect of quazodine on phosphodiesterase. , 1971 .

[35]  J. R. Vaughan,et al.  Quinazolinone Sulfonamides. A New Class of Diuretic Agents1 , 1960 .

[36]  Ji Young Kim,et al.  Synthesis and antifungal activity of 6,7-bis(arylthio)-quinazoline-5,8-diones and furo[2,3-f]quinazolin-5-ols. , 2012, Bioorganic & medicinal chemistry letters.

[37]  C. S. Rajput,et al.  Synthesis and anti-inflammatory activity of newer quinazolin-4-one derivatives. , 2009, European journal of medicinal chemistry.

[38]  T. Kurtz,et al.  Type 2 diabetes and oral antihyperglycemic drugs. , 2008, Current medicinal chemistry.

[39]  J. Blessing,et al.  Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. , 2002, Gynecologic oncology.

[40]  A. Boddy,et al.  Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  A. Caruso,et al.  Synthesis and pharmacological study of ethyl 1-methyl-5-[2-substituted-4-oxo-3(4H)-quinazolinyl]-1H-pyrazole-4-acetates , 1994 .

[42]  R. Ishida,et al.  Pharmacological studies on 6-amino-2-fluoromethyl-3-(O-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. (II) Effects on the spinal reflex potential and the rigidity. , 1982, Japanese journal of pharmacology.